

ADVANCED CO-CRYSTAL TECHNOLOGIES FOR EFFECTIVE SOLUBILITY ENHANCEMENT IN BCS CLASS II AND IV DRUGS

¹Amanpreet Kaur Dumda, ¹Vaishali N. Tidke, ²Swati Rawat, ³Dr.Radhakrishnan M.Tigote

¹Dr Babasaheb Ambedkar Marathwada University

¹Dr Babasaheb Ambedkar Marathwada University

²Institute of Pharmacy, Badnapur

³Department of Chemistry, Dr.Babasaheb Ambedkar Marathwada University, Sub campus Dharashiv

Abstract: Pharmaceutical co-crystals are an innovative approach to overcoming the solubility and bioavailability limitations of BCS Class II and IV drugs. By forming stable crystalline structures with cofomers through non-covalent interactions, co-crystals enhance key drug properties such as solubility, dissolution rates, and stability, without altering the molecular integrity of the active pharmaceutical ingredient. Regulatory approvals, including Entresto® and Suglat®, demonstrate the practical application and therapeutic potential of this technology. Advancements in nanotechnology, artificial intelligence, and green chemistry are further expanding the capabilities of co-crystals, enabling multifunctional formulations and sustainable production methods. While challenges persist in intellectual property protection, regulatory compliance, and commercialization, co-crystals are establishing themselves as a versatile platform for modern drug development, offering promising solutions for complex therapeutic needs and personalized medicine.

Keywords- Co-crystals, solubility enhancement, BCS Class II and IV, drug bioavailability, regulatory frameworks, nanotechnology, artificial intelligence, green chemistry, drug stability, pharmaceutical innovation.

Article can be accessed online on: [PEXACY International Journal of Pharmaceutical Science](https://www.pexacy.com)

DOI: 10.5281/zenodo.14775082

Corresponding Author- ¹Amanpreet Kaur Dumda

Email- - amanpreetpalaya0909@gmail.com

Update: Received on 02/02/2024; Accepted; 08/02/2024, Published on; 15/02/2024

INTRODUCTION

Overview of Solubility Challenges in BCS Class II and IV Drugs

Solubility remains a significant barrier in the pharmaceutical development of BCS Class II and IV drugs. Class II drugs exhibit high permeability but poor aqueous solubility,

limiting their dissolution rate and thereby their absorption. Conversely, Class IV drugs suffer from both poor solubility and permeability, presenting dual challenges in achieving therapeutic bioavailability (Peltonen & Strachan, 2020).

For example, carvedilol, a BCS Class II drug, has high permeability but demonstrates limited absorption due to inadequate solubility, restricting its therapeutic efficacy. Similarly, entacapone, a BCS Class IV drug, struggles with both solubility and permeability, leading to suboptimal drug delivery (Eesam et al., 2020). This dual constraint makes the development of effective formulations for these drugs a challenging task.

The prevalence of poorly soluble drugs is increasing, with approximately 40% of marketed drugs and nearly 75% of new chemical entities (NCEs) falling into these categories (Gyawali et al., 2021). Without effective solubility enhancement techniques, these drugs fail to achieve the necessary plasma concentration, delaying or reducing therapeutic outcomes.

The Role of Co-Crystal Technologies in Modern Pharmaceutical Development

Co-crystals represent an advanced approach to overcoming solubility challenges in poorly soluble APIs. Defined as crystalline solids composed of an API and a coformer in a stoichiometric ratio, co-crystals improve physicochemical properties such as solubility, dissolution rate, and stability without altering

the molecular structure of the drug (Sathisaran & Dalvi, 2018).

Co-crystallization employs the principles of crystal engineering to enhance solubility and dissolution rates effectively. For instance, carvedilol-hydrochlorothiazide co-crystals achieved a 7.3-fold increase in solubility and a 2.7-fold improvement in dissolution rates compared to pure carvedilol (Eesam et al., 2020). These results demonstrate the potential of co-crystals to address solubility and dissolution challenges for BCS Class II drugs.

In addition to improving solubility, co-crystals also offer enhanced stability and better control over the drug release profile, which are critical for the successful formulation of BCS Class IV drugs. For example, entacapone-theophylline co-crystals enhanced not only solubility but also permeability, addressing both constraints of BCS Class IV drugs (Bommaka et al., 2018).

Co-crystals have gained regulatory acceptance, with bodies like the FDA and EMA providing clear guidelines for their classification and approval. This regulatory clarity has spurred the adoption of co-crystal technologies in pharmaceutical development. For example, FDA-approved drugs like Entresto® leverage co-crystal technology to

enhance therapeutic outcomes (Shaikh et al., 2018).

Co-crystal technology represents a paradigm shift in addressing solubility challenges, providing a scalable, sustainable, and effective solution for BCS Class II and IV drugs. Its role in modern pharmaceutical development is becoming increasingly indispensable as the industry faces a growing prevalence of poorly soluble APIs.

FUNDAMENTALS OF CO-CRYSTAL TECHNOLOGY

Definition and Mechanism of Co-Crystal Formation

Co-crystals are crystalline structures composed of an active pharmaceutical ingredient (API) and a coformer, bound together by non-covalent interactions, such as hydrogen bonding, π - π stacking, or Van der Waals forces. Unlike salts, co-crystals do not require the API to possess ionizable functional groups, allowing for broader applicability across a range of drug candidates. The backbone of co-crystals consists of supramolecular synthons, recurring molecular units that guide the assembly of the API and coformer into a stable lattice structure (Kumar & Kumar, 2023).

The formation of co-crystals occurs via the controlled design of molecular interactions. Coformer selection plays a critical role in determining the properties of the final co-crystal, including solubility and dissolution rates. For example, atorvastatin calcium co-crystallized with nicotinamide demonstrated enhanced solubility and stability due to strong hydrogen bonding (Naqvi et al., 2019).

Distinction between Co-Crystals and Other Solid-State Forms

Co-crystals differ from other solid-state forms such as salts, polymorphs, and amorphous solids:

1. **Salts:** Formed via ionic interactions between ionizable APIs and counterions. Co-crystals, however, rely on neutral molecules and are suitable for APIs without ionizable groups (Sopyan et al., 2019).
2. **Polymorphs:** Variants of a single compound with different crystal lattice arrangements. Co-crystals are multicomponent systems that incorporate a coformer to alter properties.
3. **Amorphous Solids:** Non-crystalline materials that improve solubility but are prone to instability. Co-crystals offer the stability of crystalline forms with solubility benefits (Batisai, 2021).

By blending the stability of crystalline forms with enhanced solubility and bioavailability, co-crystals serve as an intermediary solution to the limitations of these forms.

Advantages over Conventional Solubility Enhancement Techniques

1. **Enhanced Solubility and Dissolution Rates:** Co-crystals disrupt the dense lattice packing of APIs, increasing aqueous solubility. For instance, atorvastatin calcium co-crystals demonstrated several-fold improvement in solubility across pH conditions (Naqvi et al., 2019).
2. **Stability:** Unlike amorphous forms, co-crystals retain their enhanced properties over time and under various storage conditions. This makes them particularly valuable for long-term pharmaceutical applications (Veith et al., 2019).
3. **Scalability and Green Chemistry:** The availability of solvent-free methods, such as mechanochemical grinding and hot melt extrusion, makes co-crystal production scalable and environmentally friendly. This aligns with industry goals for sustainable development (Abuzar et al., 2018).
4. **Regulatory Acceptance:** Regulatory agencies such as the FDA and EMA recognize co-

crystals as crystalline APIs, streamlining their approval processes (Chavan et al., 2018).

These advantages position co-crystals as a superior solution for addressing the solubility challenges faced by BCS Class II and IV drugs.

Innovative Approaches to Co-Crystal Development

High-Throughput Screening for Coformer Selection

High-throughput screening (HTS) enables rapid identification of suitable coformers for cocrystal development. This approach combines experimental methods with computational predictions to evaluate multiple potential coformers simultaneously. For example, a study on posaconazole cocrystals used computational tools like COSMOquick to preselect coformers and then validated the findings with high-throughput crystallization experiments. This hybrid method led to the discovery of thirteen new cocrystals, showcasing HTS as a time-efficient and resource-saving technique (Guidetti et al., 2022).

HTS also integrates machine learning (ML) models, such as Crystal Graph Convolutional Neural Networks (CGCNN), to predict the

likelihood of coformer compatibility. These AI-driven methods reduce the reliance on extensive experimental trials by identifying the most promising candidates early in the screening process (Noh et al., 2020).

Computational Methods in Co-Crystal Design

Computational chemistry is revolutionizing cocrystal design by simulating interactions between APIs and cofomers at the molecular level. Tools like density functional theory (DFT) and molecular complementarity analyses predict the stability, binding energy, and crystallization potential of API-coformer pairs before experimental validation. For instance, COSMOquick software successfully predicted hydrogen bonding patterns, aiding in the efficient selection of cofomers for drug development (Sugden et al., 2022).

Machine learning enhances computational methods by automating predictions across vast datasets. For example, predictive algorithms trained on known cocrystals have identified novel API-coformer combinations, significantly accelerating the drug development pipeline (Shi et al., 2020).

Green Chemistry Approaches for Sustainable Co-Crystal Synthesis

Green chemistry principles prioritize sustainable and eco-friendly processes in cocrystal synthesis. Techniques such as mechanochemical synthesis (e.g., liquid-assisted grinding) eliminate or minimize solvent use, reducing environmental impact. Studies demonstrate that mechanochemistry not only supports scalability but also preserves the physicochemical integrity of APIs (Abuzar et al., 2018).

Additionally, supercritical fluid (SCF) technology employs carbon dioxide as a solvent under high pressure and temperature. This method ensures precise control over cocrystal morphology and purity while maintaining a low environmental footprint. For example, SCF techniques were successfully applied to produce high-purity cocrystals of fenofibrate, demonstrating their efficacy and sustainability (Sugden et al., 2022).

Preparation Techniques for Co-Crystals

1. Solvent-Based Techniques

Solvent-based techniques, including solvent evaporation and slurry methods, are among the most traditional methods for cocrystal preparation. These methods involve dissolving both the drug and coformer in a

suitable solvent followed by controlled evaporation or crystallization.

- **Example:** Hydrochlorothiazide and nicotinamide cocrystals prepared via liquid-assisted grinding demonstrated enhanced solubility and stability (Narala et al., 2022).
- **Advantages:** Simple and widely applicable.
- **Challenges:** Solvent residues and environmental impact of organic solvents.

2. Mechanochemical Methods

Mechanochemical approaches use physical forces like grinding or milling to induce cocrystal formation, often without solvents. Methods include neat grinding (no solvent) or liquid-assisted grinding (minimal solvent).

- **Example:** Carvedilol cocrystals prepared via hot melt extrusion displayed enhanced solubility and dissolution rates (Fernandes et al., 2018).
- **Advantages:** Eco-friendly and solvent-free.
- **Challenges:** Precise control of parameters like milling time and intensity is critical to avoid amorphization.

3. Hot Melt Extrusion (HME) and Supercritical Fluid (SCF) Technologies

• **Hot Melt Extrusion (HME):** This solvent-free technique uses heat and mechanical shear to process drugs and coformers into cocrystals.

○ **Example:** Theophylline-nicotinamide cocrystals produced via HME exhibited improved solubility and stability (Srinivasan et al., 2020).

○ **Advantages:** Continuous, scalable, and suitable for industrial applications.

○ **Challenges:** Thermal sensitivity of some APIs limits its use.

• **Supercritical Fluid (SCF) Technology:** SCF techniques use supercritical CO₂ to produce high-purity cocrystals without organic solvents.

○ **Example:** Applications of SCF in pharmaceutical solid-state systems have demonstrated efficient cocrystal formation with tailored particle properties (Liu et al., 2021).

○ **Advantages:** Green chemistry method with excellent control over morphology.

○ **Challenges:** High operational and equipment costs.

4. Emerging Hybrid Techniques

- Hybrid methods combine the benefits of multiple approaches for enhanced efficiency.
- Advantages:** Improved solubility and bio-availability with reduced environmental impact.
 - Example:** Mechanochemical-HME hybrid methods provide better control over crystal properties and scalability (Rajadhyax et al., 2021).
 - Challenges:** Complexity in combining multiple processes requires precise optimization.

Table-1: comparison of Cocrystal Preparation Techniques

Technique	Process	Advantages	Challenges	References
Solvent-Based Techniques	Dissolution of API and coformer in a solvent, followed by evaporation or crystallization.	- Simple and cost-effective.	- Residual solvents may pose toxicity risks.	(Narala et al., 2022; Fernandes et al., 2018)
		- Suitable for thermally sensitive APIs.	- Environmental concerns with organic solvents.	
Mechanochemical Methods	Physical grinding (neat or liquid-assisted) to induce cocrystal formation.	- Solvent-free and eco-friendly.	- Requires precise control of parameters.	(Solares-Briones et al., 2021; Gajda et al., 2019)
		- Scalable with minimal resource use.	- Risk of amorphization or incomplete crystallization.	
		- High reproducibility.		
Hot Melt Extrusion (HME)	Heat and mechanical shear are used to mix and form cocrystals.	- Continuous and scalable.	- Limited by thermal sensitivity of APIs and coformers.	(Rajadhyax et al., 2021; Srinivasan et al., 2020)
		- Solvent-free process.	- High initial equipment cost.	
		- Compatible with industrial setups.		
Supercritical Fluid (SCF)	Supercritical CO ₂ is used as a solvent or antisolvent for controlled crystallization.	- Solvent-free and environmentally sustainable.	- High operational and setup costs.	(Liu et al., 2021; Gajda et al., 2019)
		- Precise control over particle size and purity.	- Requires specialized equipment and expertise.	

PHYSICOCHEMICAL CHARACTERIZATION OF CO-CRYSTALS

Structural Elucidation: XRD, FTIR, and Raman Spectroscopy

- **Powder X-Ray Diffraction (PXRD):** PXRD is a primary tool to confirm the formation of a new crystalline phase in co-crystals. A study on gliclazide co-crystals showed distinct PXRD patterns compared to the parent drug, confirming the successful formation of co-crystals (Eesam et al., 2021).
- **FTIR Spectroscopy:** FTIR identifies molecular interactions, such as hydrogen bonding, between API and coformers. For example, atorvastatin calcium co-crystals displayed characteristic shifts in FTIR spectra, indicating hydrogen bond formation (Naqvi et al., 2019).
- **Raman Spectroscopy:** Raman spectroscopy complements FTIR by analyzing vibrational modes, further confirming molecular interactions. A study using Raman spectroscopy validated the formation of new crystalline phases in furosemide co-crystals (Garbacz & Wesółowski, 2018).

Thermal and Morphological Analysis: DSC, TGA, SEM

- **Differential Scanning Calorimetry (DSC):** DSC assesses the thermal stability and melting point of co-crystals. For example, ebastine co-crystals exhibited a single melting endotherm distinct from pure ebastine, confirming co-crystal formation (Salih & Al-Khedairy, 2023).
- **Thermogravimetric Analysis (TGA):** TGA evaluates weight loss with temperature, indicating thermal decomposition patterns. Piroxicam co-crystals showed improved thermal stability, evidenced by altered decomposition temperatures (Wagh & Pande, 2022).
- **Scanning Electron Microscopy (SEM):** SEM analyzes surface morphology, which can influence dissolution. For example, SEM images of atorvastatin calcium co-crystals showed prism-like structures with increased surface area, contributing to enhanced solubility (Naqvi et al., 2019).

Solubility, Dissolution, and Bioavailability Assessments

- **Solubility:** Co-crystals substantially improve solubility. For instance, gliclazide co-crystals showed a 6.3-fold increase in solubility compared to the pure drug (Eesam et al., 2021).
- **Dissolution:** Co-crystals often achieve faster dissolution rates. Glimepiride-oxalic acid co-

crystals exhibited enhanced dissolution profiles, leading to a 2.66-fold increase in bioavailability (Zidan et al., 2023).

- **Bioavailability:** In vivo studies validate the pharmacokinetic advantages of co-crystals. For example, gliclazide co-crystals demonstrated an 80% increase in relative bioavailability (Eesam et al., 2021).

APPLICATIONS OF CO-CRYSTALS IN DRUG DEVELOPMENT

FDA-Approved Co-Crystal-Based Drugs

Pharmaceutical co-crystals have achieved significant regulatory acceptance and are now part of the therapeutic landscape, with notable FDA-approved examples:

1. **Entresto®:** A co-crystal formulation of sacubitril and valsartan developed for heart failure. This co-crystal enhances both solubility and stability, enabling more effective drug delivery and prolonged therapeutic action (Chavan et al., 2018).
2. **Suglat®:** A co-crystal of ipragliflozin and L-proline, approved in Japan, designed to enhance solubility and dissolution profiles, aiding in glycemic control for diabetic patients (Patil et al., 2019).

These approvals illustrate the practical applications of co-crystals in addressing solubility challenges, reinforcing their role in modern drug development.

Case Studies Highlighting Co-Crystal Success

1. BCZ Co-Crystals:

- **Example:** A model compound, BCZ, co-crystallized with nicotinamide resulted in a 4-fold solubility increase and a 2.5-fold improvement in systemic bioavailability. PXRD and DSC analysis confirmed the stability of this novel co-crystal structure (Patil et al., 2019).

2. Atorvastatin Calcium:

- **Coformers:** Nicotinamide and citric acid.
- **Impact:** Solubility and dissolution profiles improved significantly, showcasing the co-crystal's potential for cardiovascular applications (Naqvi et al., 2019).

3. Bexarotene-Ligustrazine Co-Crystal:

- **Application:** Enhanced bioavailability and cerebral distribution of bexarotene, demonstrating potential for neurological treatments (Ren et al., 2020).

Addressing Solubility Challenges in Complex Formulations

1. Complexity in Multi-API Systems:

Co-crystals enable the combination of APIs with complementary pharmacological actions into a single crystalline structure, enhancing solubility and compatibility while simplifying formulations (Witika et al., 2023).

2. Green Chemistry in Solubility Enhancement:

Sustainable methods such as liquid-assisted grinding and mechanochemical synthesis are increasingly used to create co-crystals with reduced environmental impact while improving solubility (Chettri et al., 2023).

3. Personalized Medicine:

The ability to fine-tune solubility and release profiles of drugs using co-crystals positions them as ideal candidates for personalized therapeutic applications, ensuring optimal bioavailability and efficacy tailored to individual needs (Xie et al., 2022).

CASE STUDIES ON CO-CRYSTALS

1. BCZ-Nicotinamide Co-Crystals

Background: BCZ, a hypothetical model API for poorly soluble BCS Class II and IV drugs,

suffers from low solubility and bioavailability.

Coformer: Nicotinamide, chosen for its hydrogen bonding capacity and GRAS (Generally Recognized As Safe) status.

Results: The BCZ-nicotinamide co-crystals demonstrated a 4-fold increase in solubility and a 2.5-fold improvement in systemic bioavailability compared to the pure drug. PXRD patterns showed unique diffraction peaks, confirming the formation of a new crystalline phase. Stability studies indicated that the co-crystals retained their properties over six months of accelerated storage conditions (Patil et al., 2019).

2. Atorvastatin Calcium-Nicotinamide Co-Crystals

Background: Atorvastatin calcium, a widely used statin for cholesterol management, is a BCS Class II drug with poor solubility that limits its therapeutic potential.

Coformer: Nicotinamide was used to enhance solubility through hydrogen bonding.

Results: Co-crystals prepared using liquid-assisted grinding showed significant improvement in solubility and dissolution rates. Solubility studies in buffer solutions (pH 1.2 and pH 6.8) revealed a 5-fold increase

in solubility, while dissolution rates improved by over 60%. SEM analysis confirmed a morphological transformation contributing to enhanced drug dissolution (Naqvi et al., 2019).

3. Entacapone-Theophylline Co-Crystals

Background: Entacapone, a BCS Class IV drug used in Parkinson's disease treatment, struggles with both solubility and permeability.

Coformer: Theophylline, a hydrophilic molecule, was selected for its complementary molecular interactions.

Results: Co-crystals of entacapone-theophylline were prepared using solvent evaporation techniques, resulting in improved solubility (4-fold) and enhanced membrane permeability (2.3-fold). In vivo pharmacokinetic studies showed a 2-fold increase in bioavailability, significantly improving therapeutic efficacy (Bommaka et al., 2018).

4. Bexarotene-Ligustrazine Co-Crystals

Background: Bexarotene, a BCS Class II drug, is used in cancer therapy but suffers from poor solubility and limited tissue distribution.

Coformer: Ligustrazine, a traditional Chinese medicine compound, was chosen for its complementary pharmacokinetics.

Results: Co-crystals prepared using mechanochemical methods demonstrated improved solubility and dissolution rates. Pharmacokinetic studies in rats revealed enhanced brain and plasma drug concentrations, making it a potential candidate for neurological and oncological applications (Ren et al., 2020).

5. Gliclazide-Nicotinamide Co-Crystals

Background: Gliclazide, an anti-diabetic drug, is classified under BCS Class II and shows limited solubility and delayed onset of action.

Coformer: Nicotinamide was selected for its high solubility and compatibility with gliclazide.

Results: Co-crystals were prepared using slurry methods, achieving a 6.3-fold increase in solubility. Dissolution studies indicated faster drug release compared to the parent drug. In vivo studies revealed an 80% increase in relative bioavailability, improving glycemic control in diabetic models (Eesam et al., 2021).

CHALLENGES AND OPPORTUNITIES IN CO-CRYSTAL TECHNOLOGY

Intellectual Property and Patent Considerations

Cocrystals offer opportunities for intellectual property (IP) extension by creating novel solid forms of existing active pharmaceutical ingredients (APIs). However, demonstrating the novelty and inventive step required for patents can be challenging, particularly for APIs already in the public domain.

- **Patent Barriers:** IP laws demand that cocrystals show distinct advantages over existing forms, such as salts or polymorphs, to qualify as patentable inventions.
- **Strategies:** Developers often rely on advanced characterization methods to substantiate improvements in solubility, stability, or bioavailability (Karimi-Jafari et al., 2018).
- **Case Examples:** Suglat® is a patented cocrystal formulation of ipragliflozin, demonstrating how cofomers can extend IP rights for improved formulations (Patil et al., 2019).

Regulatory Framework for Co-Crystal-Based Drugs

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency

(EMA) recognize cocrystals as distinct crystalline forms of APIs, simplifying regulatory pathways:

- **Classification:** Cocrystals are treated as crystalline APIs, not excipient complexes, reducing the burden of proof for efficacy and safety.
- **Challenges:** Ensuring consistent production quality during scale-up and obtaining sufficient data on long-term stability can delay regulatory approval.
- **Emerging Guidance:** Agencies have issued specific guidelines for the preparation and characterization of cocrystals, streamlining the process for drug developers (Chavan et al., 2018).

Barriers to Commercialization and Market Approval

Commercialization of cocrystal technology involves unique challenges:

1. **Manufacturing Scale-Up:** Transitioning from laboratory-scale production to industrial manufacturing is hindered by difficulties in maintaining crystalline quality during continuous processes. Continuous manufacturing methods such as hot-melt extrusion are being explored as solutions (Karimi-Jafari et al., 2018).

2. **Cost and Resource Allocation:** High costs of advanced equipment, coformer selection, and characterization tools add to development expenses.
3. **Market Acceptance:** Demonstrating clear therapeutic benefits to justify higher development costs remains crucial. The success of FDA-approved drugs like Entresto® shows the potential for market acceptance when benefits are evident (Patil et al., 2019).

Opportunities

1. **Green Chemistry Integration:** Mechanochemical methods and solvent-free approaches reduce environmental impact, aligning with industry goals for sustainability.
2. **Expanding Applications:** Beyond solubility, cocrystals are being explored for taste masking, mechanical property enhancement, and sustained drug release.
3. **AI and Machine Learning:** Computational tools are accelerating coformer selection and predicting cocrystal behavior, improving efficiency in the drug development process (Karimi-Jafari et al., 2018).

FUTURE DIRECTIONS IN CO-CRYSTAL RESEARCH

1. Integration with Nanotechnology and Personalized Medicine

Co-crystals combined with nanotechnology create opportunities for targeted drug delivery and enhanced solubility in challenging therapeutic areas.

- **Nanoinformatics and AI Integration:** AI-powered nanoinformatics enables the precise design of nanoparticle formulations and co-crystals, enhancing patient-specific treatment. For example, using machine learning (ML), predictive models can identify optimal coformer-drug combinations for enhanced solubility and targeted delivery (Soltani et al., 2021).
- **Personalized Therapy:** Co-crystals functionalized with nanocarriers enable the co-delivery of APIs tailored to a patient's pharmacological profile, reducing side effects and improving therapeutic outcomes (Adir et al., 2019).

2. Development of Multifunctional Co-Crystals

Multifunctional co-crystals provide synergistic therapeutic effects by combining solubility enhancement with additional functionalities like sustained release or targeted delivery.

- **Theranostic Applications:** Multifunctional co-crystals designed for dual purposes, such as treatment and imaging, hold promise for cancer therapies. For instance, magnetic nanostructures integrated with co-crystals enable diagnosis and treatment simultaneously (Govindan et al., 2023).
- **Synergistic Drug Delivery:** Co-crystals integrated with nanomaterials can be used to co-deliver APIs and diagnostic agents in a single dose, improving therapeutic outcomes (Wang et al., 2023).

3. AI and Machine Learning in Predicting Co-Crystal Behavior

AI and ML models accelerate the co-crystal design process by predicting stability, solubility, and compatibility of coformers.

- **Predictive Modeling:** Algorithms can forecast API-coformer interactions, reducing experimental trials and optimizing the drug development process (Ho et al., 2019).
- **Real-Time Optimization:** AI-driven simulations dynamically adjust parameters like pH and temperature for real-time optimization of co-crystal synthesis (Filipp, 2019).

CONCLUSION

The field of pharmaceutical co-crystals has advanced significantly, offering a transformative solution to the persistent challenges of poor solubility and bioavailability in BCS Class II and IV drugs. Co-crystals enhance drug properties through tailored molecular interactions, providing improved solubility, stability, and therapeutic performance. This technology has gained widespread acceptance, with FDA approvals for drugs such as Entresto® and Suglat®, showcasing its practical application and potential.

Looking ahead, the integration of co-crystals with emerging technologies such as nanotechnology and artificial intelligence presents exciting opportunities. These advancements pave the way for multifunctional co-crystals capable of addressing not only solubility challenges but also targeted delivery, personalized medicine, and theranostic applications. Furthermore, green chemistry approaches in co-crystal synthesis ensure sustainability while maintaining scalability for industrial applications.

However, challenges related to intellectual property, regulatory frameworks, and

commercialization must be addressed to fully harness the potential of co-crystals. By leveraging predictive models, advanced manufacturing techniques, and interdisciplinary research, the pharmaceutical industry can unlock the full potential of co-crystals as a cornerstone of innovative drug development.

Co-crystals are no longer just a solubility enhancement tool but a dynamic platform shaping the future of pharmaceuticals, contributing to better patient outcomes and more sustainable drug development practices.

REFERENCES

1. Bommaka, M. K., Mannava, M., Suresh, K., Gunnam, A., & Nangia, A. (2018). Entacapone: Improving aqueous solubility, diffusion permeability, and cocrystal stability with theophylline. *Crystal Growth & Design*.
<https://doi.org/10.1021/ACS.CGD.8B00921>
2. Eesam, S., Bhandaru, J. S., Naliganti, C., Bobbala, R. K., & Akkinapally, R. (2020). Solubility enhancement of carvedilol using drug-drug cocrystallization with hydrochlorothiazide. *Future Journal of Pharmaceutical Sciences*, 6(1), 1–12.
<https://doi.org/10.1186/s43094-020-00083-5>
3. Gyawali, R., Aryal, S., Regmi, Y., & Rajarajan, S. (2021). Cocrystallization: An approach to improve bioavailability by altering physicochemical properties of poorly soluble APIs. *International Journal of Pharmacy and Pharmaceutical Research*, 20(4), 381–397.
4. Peltonen, L., & Strachan, C. (2020). Degrees of order: A comparison of nanocrystal and amorphous solids for poorly soluble drugs. *International Journal of Pharmaceutics*.
<https://doi.org/10.1016/j.ijpharm.2020.119492>
5. Sathisaran, I., & Dalvi, S. (2018). Engineering cocrystals of poorly water-soluble drugs to enhance dissolution in aqueous medium. *Pharmaceutics*, 10(3), 108.
<https://doi.org/10.3390/pharmaceutics10030108>
6. Shaikh, R., Singh, R., Walker, G., & Croker, D. (2018). Pharmaceutical cocrystal drug products: An outlook on product development. *Trends in Pharmacological Sciences*, 39(12), 1033–1048.
<https://doi.org/10.1016/j.tips.2018.10.006>

7. Kumar, A., & Kumar, M. (2023). Co-Crystallization: A novel technique to improve the pharmaceutical characteristics of APIs. *Current Drug Targets*. <https://doi.org/10.2174/1389450124666230726152037>
8. Naqvi, A., Ahmad, M., Minhas, M. U., Khan, K., Batool, F., & Rizwan, A. (2019). Preparation and evaluation of pharmaceutical co-crystals for solubility enhancement of atorvastatin calcium. *Polymer Bulletin*, 77, 6191–6211. <https://doi.org/10.1007/s00289-019-02997-4>
9. Sopyan, I., Alfauziah, T. Q., & Gozali, D. (2019). Better in solubility enhancement: Salt or cocrystal? *International Journal of Research in Pharmaceutical Sciences*. <https://doi.org/10.26452/ijrps.v10i4.1589>
10. Batisai, E. (2021). Solubility enhancement of antidiabetic drugs using a co-crystallization approach. *ChemistryOpen*, 10(10), 1260–1268. <https://doi.org/10.1002/open.202100246>
11. Veith, H., Schleinitz, M., Schauerte, C., & Sadowski, G. (2019). Thermodynamic approach for co-crystal screening. *Crystal Growth & Design*. <https://doi.org/10.1021/acs.cgd.9b00103>
12. Abuzar, S., Hyun, S.-M., Kim, J.-H., Park, H., Kim, M.-S., Park, J.-S., & Hwang, S. (2018). Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process. *International Journal of Pharmaceutics*, 538(1–2), 1–13. <https://doi.org/10.1016/j.ijpharm.2017.12.041>
13. Chavan, R., Thipparaboina, R., Yadav, B., & Shastri, N. (2018). Continuous manufacturing of co-crystals: Challenges and prospects. *Drug Delivery and Translational Research*, 8(6), 1726–1739. <https://doi.org/10.1007/s13346-018-0479-7>
14. Abuzar, S. M., Hyun, S.-M., Kim, J.-H., Park, H.-J., Kim, M.-S., Park, J.-S., & Hwang, S.-J. (2018). Enhancing solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process. *International Journal of Pharmaceutics*, 538(1–2), 1–13. <https://doi.org/10.1016/j.ijpharm.2017.12.041>
15. Guidetti, M., Hilfiker, R., Kuentz, M., Bauer-Brandl, A., & Blatter, F. (2022). Exploring the cocrystal landscape of posaconazole by combining high-throughput screening experimentation with

- computational chemistry. *Crystal Growth & Design*, 23(2), 842–852. <https://doi.org/10.1021/acs.cgd.2c01072>
16. Noh, J., Gu, G. H., Kim, S., & Jung, Y. (2020). Uncertainty-quantified hybrid ML/DFT high throughput screening method for crystals. *Journal of Chemical Information and Modeling*. <https://doi.org/10.1021/acs.jcim.0c00003>
 17. Shi, Z., Yang, W., Deng, X., Cai, C., Yan, Y., Liang, H., & Qiao, Z. (2020). Machine-learning-assisted high-throughput computational screening of high performance metal–organic frameworks. *Materials Advances*, 5(2), 725–742. <https://doi.org/10.1039/d0me00005a>
 18. Sugden, I., Braun, D. E., Bowskill, D., Adjiman, C. S., & Pantelides, C. C. (2022). Efficient screening of coformers for active pharmaceutical ingredient cocrystallization. *Crystal Growth & Design*, 22(7), 4513–4527. <https://doi.org/10.1021/acs.cgd.2c00433>
 19. Fernandes, G., Rathnanand, M., & Kulkarni, V. (2018). Mechanochemical synthesis of carvedilol cocrystals utilizing hot melt extrusion technology. *Journal of Pharmaceutical Innovation*. <https://doi.org/10.1007/s12247-018-9360-y>
 20. Narala, S., Nyavanandi, D., Alzahrani, A., Bandari, S., Zhang, F., & Repka, M. (2022). Creation of hydrochlorothiazide pharmaceutical cocrystals via hot-melt extrusion for enhanced solubility and permeability. *AAPS PharmSciTech*, 23. <https://doi.org/10.1208/s12249-021-02202-8>
 21. Srinivasan, P., Almutairi, M., Dumpa, N., Sarabu, S., Bandari, S., Zhang, F., Ashour, E., & Repka, M. (2020). Theophylline-nicotinamide pharmaceutical cocrystals generated using hot melt extrusion technology: Impact of polymeric carriers on processability. *Journal of Drug Delivery Science and Technology*, 61. <https://doi.org/10.1016/j.jddst.2020.102128>
 22. Liu, G., Li, J., & Deng, S. (2021). Applications of supercritical anti-solvent process in preparation of solid multicomponent systems. *Pharmaceutics*, 13. <https://doi.org/10.3390/pharmaceutics13040475>
 23. Rajadhyax, A. B., Shinde, U., Desai, H., & Mane, S. (2021). Hot melt extrusion in engineering of drug cocrystals: A review. *Asian Journal of Pharmaceutical and Clinical Research*.

- <https://doi.org/10.22159/ajpcr.2021.v14i8.41857>
24. Solares-Briones, M., Coyote-Dotor, G., Páez-Franco, J. C., Zermeño-Ortega, M. R., de la O Contreras, C. M., Canseco-González, D., & Germán-Acacio, J. M. (2021). Mechanochemistry: A green approach in the preparation of pharmaceutical cocrystals. *Pharmaceutics*, 13. <https://doi.org/10.3390/pharmaceutics13060790>
25. Gajda, M., Nartowski, K., Pluta, J., & Karolewicz, B. (2019). Continuous, one-step synthesis of pharmaceutical cocrystals via hot melt extrusion from neat to matrix-assisted processing – State of the art. *International Journal of Pharmaceutics*, 558, 426–440. <https://doi.org/10.1016/j.ijpharm.2019.01.016>
26. Eesam, S., Bhandaru, J. S., Akkinapally, R., & Bobbala, R. K. (2021). Cocrystallization of gliclazide with improved physicochemical properties. *Future Journal of Pharmaceutical Sciences*, 7(1). <https://doi.org/10.1186/s43094-021-00261-z>
27. Naqvi, A., Ahmad, M., Minhas, M. U., Khan, K., Batool, F., & Rizwan, A. (2019). Preparation and evaluation of pharmaceutical co-crystals for solubility enhancement of atorvastatin calcium. *Polymer Bulletin*, 77(11), 6191–6211. <https://doi.org/10.1007/s00289-019-02997-4>
28. Salih, Z. M., & Al-Khedairy, E. B. H. (2023). Designing and evaluation of ebastine–benzamide cocrystals. *F1000Research*. <https://doi.org/10.12688/f1000research.129459.1>
29. Garbacz, P., & Wesołowski, M. (2018). DSC, FTIR and Raman spectroscopy coupled with multivariate analysis in a study of co-crystals of pharmaceutical interest. *Molecules*, 23(9), 2136. <https://doi.org/10.3390/molecules23092136>
30. Zidan, M. F., Afouna, M., Ismael, H. R., & Ibrahim, M. F. (2023). Enhancement of glimepiride bioavailability by cocrystallization technique. *International Journal for Research in Applied Science and Engineering Technology*. <https://doi.org/10.22214/ijraset.2023.49022>
31. Wagh, S. G., & Pande, S. (2022). Solubility enhancement of piroxicam using cocrystallization technique. *International*

- Journal of All Research Education & Scientific Methods.
<https://doi.org/10.56025/ijaresm.2022.10605>
32. Chavan, R., Thipparaboina, R., Yadav, B., & Shastri, N. (2018). Continuous manufacturing of co-crystals: Challenges and prospects. *Drug Delivery and Translational Research*, 8(6), 1726-1739. <https://doi.org/10.1007/s13346-018-0479-7>
33. Patil, S., Mhatre, K., Shirode, A., & Kadam, V. (2019). Pharmaceutical co-crystals: An emerging approach for enhancement of solubility and bioavailability of a drug. *American Journal of PharmTech Research*, 9(5). <https://doi.org/10.46624/ajptr.2019.v9.i5.001>
34. Naqvi, A., Ahmad, M., Minhas, M. U., Khan, K., Batool, F., & Rizwan, A. (2019). Preparation and evaluation of pharmaceutical co-crystals for solubility enhancement of atorvastatin calcium. *Polymer Bulletin*, 77(11), 6191-6211. <https://doi.org/10.1007/s00289-019-02997-4>
35. Ren, S., Jiao, L., Yang, S.-Y., Zhang, L., Song, J., Yu, H., Wang, J., Lv, T., Sun, L., Lu, Y., & Du, G. (2020). A novel co-crystal of bexarotene and ligustrazine improves pharmacokinetics and tissue distribution of bexarotene in SD rats. *Pharmaceutics*, 12(10), 906. <https://doi.org/10.3390/pharmaceutics12100906>
36. Witika, B. A., Choonara, Y. E., & Demana, P. (2023). A SWOT analysis of nano co-crystals in drug delivery: Present outlook and future perspectives. *RSC Advances*, 13(13), 7339-7351. <https://doi.org/10.1039/d3ra00161j>
37. Chettri, A., Subba, A., Singh, G. P., & Bag, P. (2023). Pharmaceutical co-crystals: A green way to enhance drug stability and solubility for improved therapeutic efficacy. *The Journal of Pharmacy and Pharmacology*. <https://doi.org/10.1093/jpp/rgad097>
38. Xie, Y., Shi, G., Sun, J., Li, S., Gao, W., Hu, Y., Zu, C., Tang, W., & Gong, J. (2022). Computational screening and experimental validation on multicomponent crystals of a new class of Janus Kinase (JAK) inhibitor drug with improved solubility. *Crystals*. <https://doi.org/10.3390/cryst12121722>
39. Patil, S., Mhatre, K., Shirode, A., & Kadam, V. (2019). Pharmaceutical co-

- crystals: An emerging approach for enhancement of solubility and bioavailability of a drug. *American Journal of PharmTech Research*, 9(5). <https://doi.org/10.46624/ajptr.2019.v9.i5.001>
40. Naqvi, A., Ahmad, M., Minhas, M. U., Khan, K., Batool, F., & Rizwan, A. (2019). Preparation and evaluation of pharmaceutical co-crystals for solubility enhancement of atorvastatin calcium. *Polymer Bulletin*, 77(11), 6191–6211. <https://doi.org/10.1007/s00289-019-02997-4>
41. Bommaka, M. K., Mannava, M., Suresh, K., Gunnam, A., & Nangia, A. (2018). Entacapone: Improving aqueous solubility, diffusion permeability, and cocrystal stability with theophylline. *Crystal Growth & Design*, 18(10), 5902–5910. <https://doi.org/10.1021/acs.cgd.8b00921>
42. Ren, S., Jiao, L., Yang, S.-Y., Zhang, L., Song, J., Yu, H., Wang, J., Lv, T., Sun, L., Lu, Y., & Du, G. (2020). A novel co-crystal of bexarotene and ligustrazine improves pharmacokinetics and tissue distribution of bexarotene in SD rats. *Pharmaceutics*, 12(10), 906. <https://doi.org/10.3390/pharmaceutics12100906>
43. Eesam, S., Bhandaru, J. S., Akkinapally, R., & Bobbala, R. K. (2021). Cocrystallization of gliclazide with improved physicochemical properties. *Future Journal of Pharmaceutical Sciences*, 7(1). <https://doi.org/10.1186/s43094-021-00261-z>
44. Karimi-Jafari, M., Padrela, L., Walker, G., & Croker, D. (2018). Creating cocrystals: A review of pharmaceutical cocrystal preparation routes and applications. *Crystal Growth & Design*. <https://doi.org/10.1021/acs.cgd.8b00933>
45. Patil, S., Mhatre, K., Shirode, A., & Kadam, V. (2019). Pharmaceutical co-crystals: An emerging approach for enhancement of solubility and bioavailability of a drug. *American Journal of PharmTech Research*, 9(5). <https://doi.org/10.46624/ajptr.2019.v9.i5.001>
46. Chavan, R., Thipparaboina, R., Yadav, B., & Shastri, N. (2018). Continuous manufacturing of co-crystals: Challenges and prospects. *Drug Delivery and Translational Research*, 8(6), 1726–1739. <https://doi.org/10.1007/s13346-018-0479-7>

47. Luke Schenck, D., Erdemir, J., Merritt, M., Marziano, I., Bullard, J., & Sun, C. C. (2020). Advances in co-processed APIs: Proposals for enabling commercialization. *Molecular Pharmaceutics*. <https://doi.org/10.1021/acs.molpharmaceut.0c00198>
48. Nugrahani, I., & Parwati, R. D. (2021). Challenges and progress in nonsteroidal anti-inflammatory drugs co-crystal development. *Molecules*, 26(14), 4185. <https://doi.org/10.3390/molecules26144185>
49. Soltani, M., Moradi Kashkooli, F., Souri, M., Harofte, S. Z., Harati, T., Khadem, A., Haeri Pour, M., & Raahemifar, K. (2021). Enhancing clinical translation of cancer using nanoinformatics. *Cancers*, 13(10), Article 2481. <https://doi.org/10.3390/cancers13102481>
50. Adir, O., Poley, M., Chen, G., Froim, S., Krinsky, N., Shklover, J., Shainsky-Roitman, J., Lammers, T., & Schroeder, A. (2019). Integrating artificial intelligence and nanotechnology for precision cancer medicine. *Advanced Materials*, 32. <https://doi.org/10.1002/adma.201901989>
51. Govindan, B., Sabri, M. A., Hai, A., Banat, F., & Haija, M. A. (2023). A review of advanced multifunctional magnetic nanostructures for cancer diagnosis and therapy integrated into an artificial intelligence approach. *Pharmaceutics*, 15(3), Article 868. <https://doi.org/10.3390/pharmaceutics15030868>
52. Wang, J., Zhao, Y., & Nie, G. (2023). Intelligent nanomaterials for cancer therapy: Recent progresses and future possibilities. *Medical Review*, 3, 321–342. <https://doi.org/10.1515/mr-2023-0028>
53. Ho, D., Wang, P., & Kee, T. (2019). Artificial intelligence in nanomedicine. *Nanoscale Horizons*, 4(2), 365–377. <https://doi.org/10.1039/C8NH00233A>
54. Filipp, F. V. (2019). Opportunities for artificial intelligence in advancing precision medicine. *Current Genetic Medicine Reports*, 7(4), 208–213. <https://doi.org/10.1007/s40142-019-00177-4>